Search for: "US v. John Doe" Results 8341 - 8360 of 11,118
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
27 Jun 2011, 3:56 pm by Emma Llanso
CDT organized a coalition of Internet industry groups and others to file a friend-of-the-court brief in this case in September, and CDT’s John Morris reported on the oral arguments before the Court this past November. [read post]
27 Jun 2011, 1:15 pm by Lyle Denniston
Two years ago, Justice Scalia wrote for a 5-4 majority that the FCC does have authority, under a law dating back to 1927, to forbid the broadcast of any single use of the F-word or the S-word. [read post]
27 Jun 2011, 12:03 pm by Jo-Ann Wallace
  I hope that John Pollock’s optimism in that regard proves true, but with many states facing the bleakest fiscal outlook on record, advocates must turn a keen eye to ensuring that Turner does not signal a retreat from existing rights. [read post]
27 Jun 2011, 10:11 am by David Kravets
“This is not to say that corporations do not have correspondence, influence, or tragedies of their own, only that we do not use the word ‘personal’ to describe them,” (.pdf) Chief Justice John Roberts wrote for the court. [read post]
27 Jun 2011, 8:41 am by Kali Borkoski
Novo Nordisk A/S Docket: 10-844 Issue(s): Whether the counterclaim provision of the Hatch-Waxman Act applies when (1) there is “an approved method of using the drug” that “the patent does not claim,” and (2) the brand submits “patent information” to the FDA that misstates the patent’s scope, requiring “correct[ion]. [read post]
26 Jun 2011, 8:56 am by Paul Horwitz
 One needn't expect more, I suppose, but it's not exactly high-order journalism -- more a skillful use of the ctrl-V function. [read post]
24 Jun 2011, 3:25 pm by Christa Culver
Novo Nordisk A/SDocket: 10-844Issue(s): Whether the counterclaim provision of the Hatch-Waxman Act applies when (1) there is “an approved method of using the drug” that “the patent does not claim,” and (2) the brand submits “patent information” to the FDA that misstates the patent's scope, requiring “correct[ion]. [read post]
24 Jun 2011, 8:43 am by Kiera Flynn
  David Savage at the Los Angeles Times has coverage of both Sorrell and PLIVA, as does Jess Bravin of the Wall Street Journal. [read post]